A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Study Overview
=================
Brief Summary
-----------------
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Detailed Description
-----------------
Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Official Title
-----------------
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Conditions
-----------------
Prostate Cancer Metastatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathological confirmation of prostate cancer Age: ≥40 years old Bone or visceral metastatic disease confirmed by image examination. Written informed consent Exclusion Criteria: Patients harbouring other types of cancer besides prostate cancer

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic profiling results | Mutation identified via whole-genome sequencing will be recored. | From baseline (initial diagnosis of PCa), until study completion (48 months) | 
| Transcriptional profiling results | Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing | From baseline (initial diagnosis of PCa), until study completion (48 months) | 
| Epigenomic profiling results | Determining the epigenomic status of specific genes by performing DNA-methylation sequencing | From baseline (initial diagnosis of PCa), until study completion (48 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Protein expression results | Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen | From baseline (initial diagnosis of PCa), until study completion (48 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genomic sequencing, Transcriptome sequencing, Epigenetics, Metabonomics, Immunohistochemical, Multi-omics Study